Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Paul Grint, Bruce Huebner, Thomas McLain

Premium

Illumina said in a recent filing with the US Securities and Exchange Commission that Paul Grint plans to retire from the firm's board of directors, effective as of the next Illumina stockholder meeting.

Grint has been a director since 2005. He's currently senior vice president at Forest Research Institute, and was previously the chief medical officer at Kalypsys. He has also served as an executive at Zephyr Sciences, Pfizer, IDEC Pharmaceuticals, and Schering-Plough.


Vermillion has appointed Bruce Huebner to be company chairman. Huebner had been serving as Vermillion's interim CEO and president until earlier this month when the company earlier named Thomas McLain to those positions.

Prior to joining Vermillion, Huebner held various managerial posts in the life sciences and healthcare industries. From 2005 to 2008, he served as president of Osmetech Molecular Diagnostics, now GenMark Diagnostics. And from 2002 and 2004, he was president and chief operating officer of Nanogen.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.